Quotient's technology is rooted in the groundbreaking work of Dr. William Pollack, a visionary in human-antibody technology. His son, David Pollack, who Dr. Pollack mentored for over two decades, has continued to drive this innovation. Decades before his involvement with Quotient, Dr. Pollack spearheaded research and development at Johnson & Johnson's Ortho. The Ortho family of companies, renowned for its extensive antibody research, developed antibody-based pharmaceuticals that have significantly impacted modern medicine, saving millions of lives.

 

One of Dr. Pollack’s most significant achievements, RhoGAM, virtually eradicated Rh disease. Widely regarded as the most important product ever created for women's health, it has saved over 60 million babies from the often-fatal consequences of Rh incompatibility. Approved by the Food & Drug Administration in 1969 as RhoGAM, Rh-Immune Globulin remains the global standard of care, administered to millions of women annually.

 

RhoGAM functions by using "blocking" antibodies to intercept foreign antigens before they can trigger an immune response in pregnant women against their fetuses. These blocking antibodies are derived from specific donors, a process similar to Quotient's current technology platform. With over 250 million doses administered safely, RhoGAM consistently blocks the immune response. Dr. Pollack also led the development of Hepatitis B Immune Globulin (HBIG), which provides immediate passive hyper-immunity against Hepatitis B. RhoGAM is recognized on the World Health Organization's list of Essential Medicines. In 1980, Dr. Pollack received the Lasker Award, often called the "American Nobel Prize," for his excellence in biomedical research and contributions to medicine and health. He was honored as "A bold and knowledgeable immunologist with a thorough understanding of the new technology for fractionating serum into its constituents."

 

Through years of continuous study with Dr. Pollack, numerous patents, proprietary process refinements, development of manufacturing facilities, and extensive testing, Quotient is now prepared to begin submissions for advancing this revolutionary treatment platform.